Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications ...

Danish start-up Fuse Vectors has received $5.2 million in preseed financing to further develop their gene therapy technology.

These little vessels help in the grand scientific effort to understand the mechanisms of disease and to mitigate illness. One such virus, the adeno-associated virus (AAV), is the secret to gene ...

The company’s team of experts initially identifies and selects suitable diseases, in which single-dose AAV gene therapy is expected to either increase or decrease the production of a specific ...

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications ...

However, scaling up AAV manufacturing to obtain sufficient yields to meet the demands of new research initiatives and clinical applications is challenging using traditional approaches. Download this ...

During AAV production, natural variations in the viral genome lead to the formation of subpopulations within a single batch. These variations can negatively impact the efficiency of the vector ...

The funding will accelerate the development of Fuse's technology platform and pipeline of novel gene therapies. With its breakthrough approach, Fuse Vectors aims to be the universal solution for AAV ...

Production system: Today's launch introduces Asimov’s transient transfection-based AAV manufacturing system—the first in a ...

NewBiologix, a technology innovation company pioneering efficient, cost-effective, and scalable production of viral vectors for gene and cell therapy, today released a scientific white paper outlining ...